Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 29 · below the Ichimoku cloud · RSI 34 · MACD below its signal
None of the 29 investors followed here reported a position in NCNA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No insider transactions reported for NCNA.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -30.3 | -13.9 | -35.2 | 52.1 | 9.4 | -34.8 | -13.2 | 11.4 | -8.2 | -22.2 | −70.8% | ||
| 2025 | -14.3 | -4.9 | -10.0 | -32.4 | -94.1 | 62.9 | -24.6 | -62.9 | 45.5 | -13.6 | 6.7 | -15.9 | −98.5% |
| 2024 | 1.4 | 6.7 | -18.8 | -39.1 | -8.8 | -29.4 | 42.7 | 0.5 | -37.2 | -29.6 | -19.8 | -8.5 | −83.9% |
| 2023 | 128.8 | -4.0 | -33.8 | -11.6 | -1.6 | -5.4 | -3.8 | -5.3 | -15.3 | -19.7 | -15.7 | -28.3 | −55.2% |
| 2022 | 19.7 | -5.3 | -63.0 | -29.6 | -16.4 | 23.3 | 153.8 | -21.2 | -27.9 | -4.3 | -14.6 | -22.7 | −72.3% |
| 2021 | 28.7 | -8.7 | -5.5 | -13.0 | -29.5 | -9.5 | -23.5 | 25.5 | -3.0 | -6.2 | 12.8 | -12.8 | −47.0% |
| 2020 | -12.8 | -22.7 | 41.8 | -3.1 | 11.0 | -13.7 | 2.6 | -0.2 | -6.7 | -8.5 | -3.6 | -1.5 | −26.4% |
| 2019 | -10.6 | -8.2 | 42.9 | -11.8 | -20.0 | -13.5 | -17.1 | 5.5 | -20.3 | -3.0 | 20.8 | -28.1 | −57.9% |
| 2018 | 142.4 | -20.7 | -2.6 | 25.0 | 14.9 | -30.1 | 11.1 | 17.8 | 0.2 | -28.9 | 10.0 | -25.6 | +43.4% |
| 2017 | -38.2 | 8.3 | -17.8 | −45.0% |
No member of Congress has disclosed a NCNA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.